Abstract
Postherpetic neuralgia (PHN) profoundly affects health-related quality of life and functional status of patients. In addition to pain, often sleep disturbances or anxiety/depression are present (“triad of pain“). While the prevalence of PHN in herpes zoster patients is high (ca. 11%), it is difficult to treat and often refractory to available therapies. Pregabalin, a highly selective ligand for the alpha2-delta subunit protein of voltage-gated calcium channels, reduces release of excitatory neurotransmitters. It is approved for, among other indications, the treatment of peripheral and central neuropathic pain. We aimed to assess its efficacy and safety in general practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
